RxDoctor Payments Data

Vanessa Meade

Family · Pikeville, KYNPI 1649663659

Payments from drug & device makers

$4,481in general payments, 2019–2025

Across 316 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Pfizer$663
  • Johnson & Johnson$398
  • Boehringer Ingelheim$394
  • Abbott$355
  • Merck$274
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,481 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$25,491
Medicare patients
337
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban409$358,005
EntrestoSacubitril/Valsartan274$237,130
XareltoRivaroxaban111$88,883
FarxigaDapagliflozin Propanediol98$64,360
BrilintaTicagrelor88$50,046
LeqvioInclisiran Sodium14$43,964
JardianceEmpagliflozin24$22,948
Repatha SureclickEvolocumab30$20,696
VerquvoVericiguat13$12,188
Ranolazine ErRanolazine99$9,952
Praluent PenAlirocumab13$6,312
Metoprolol Succinate488$3,483
Digoxin47$2,890
Bisoprolol Fumarate151$2,149
Prasugrel Hcl14$1,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$663$358,005409 claims
NovartisEntresto, Leqvio$1,207$281,095288 claims
AstraZenecaFarxiga, Brilinta$79$114,406186 claims
Johnson & JohnsonXarelto$398$88,883111 claims
Boehringer IngelheimJardiance$394$22,94824 claims
MerckVerquvo$274$12,18813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Pikeville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →